CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation*

The activity of cyclin-dependent kinase 2 (CDK2) is essential for progression of cells from G1 to the S phase of the mammalian cell cycle. CVT-313 is a potent CDK2 inhibitor, which was identified from a purine analog library with an IC50 of 0.5 μm in vitro. Inhibition was competitive with respect to ATP (K i = 95 nm), and selective CVT-313 had no effect on other, nonrelated ATP-dependent serine/threonine kinases. When added to CDK1 or CDK4, a 8.5- and 430-fold higher concentration of CVT-313 was required for half-maximal inhibition of the enzyme activity. In cells exposed to CVT-313, hyperphosphorylation of the retinoblastoma gene product was inhibited, and progression through the cell cycle was arrested at the G1/S boundary. The growth of mouse, rat, and human cells in culture was also inhibited by CVT-313 with the IC50 for growth arrest ranging from 1.25 to 20 μm. To evaluate the effects of CVT-313 in vivo, we tested this agent in a rat carotid artery model of restenosis. A brief intraluminal exposure of CVT-313 to a denuded rat carotid artery resulted in more than 80% inhibition of neointima formation. These observations suggest that CVT-313 is a promising candidate for evaluation in other disease models related to aberrant cell proliferation.

[1]  L. Tsai,et al.  The cdk2 kinase is required for the G1-to-S transition in mammalian cells. , 1993, Oncogene.

[2]  S. van den Heuvel,et al.  Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.

[3]  R. Pepperkok,et al.  Cyclin A is required at two points in the human cell cycle. , 1992, The EMBO journal.

[4]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[5]  L. Cornelius,et al.  Facile Preparation of 2,6-Disubstituted Purines Using Solid-Phase Chemistry. , 1997, The Journal of organic chemistry.

[6]  Peter G. Schultz,et al.  A Structure-Based Library Approach to Kinase Inhibitors , 1996 .

[7]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[8]  J. Pines,et al.  The cell cycle kinases. , 1994, Seminars in cancer biology.

[9]  T. Ogihara,et al.  Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. , 1994, The Journal of clinical investigation.

[10]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[11]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[12]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[13]  David O. Morgan,et al.  A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase , 1994, Cell.

[14]  W. Zhou,et al.  Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. , 1994, Biochemical and biophysical research communications.

[15]  C. Sherr.  Cancer Cell Cycles , 1996, Science.